No Data
No Data
The Singapore Government Investment Corporation sold 21.417,200 common shares of Nuochengjianhua (09969.HK), worth approximately HK$106 million
On April 17, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 17, the Singapore Government Investment Corporation (GIC (Ventures) Pte. Ltd.) sold $21.417,200 common shares worth approximately HK$106 million at an average price of HK$4.9583 per share on April 11. After the sale, the latest number of shares held by the Singapore Government Investment Corporation was 87.998 million shares, and the good position ratio dropped from 6.21% to 4.99%. This transaction involves other related parties: GIC Private L
King Bridge Investments Limited sold 310,000 shares of Nuochengjianhua (09969.HK) common shares worth approximately HK$1,520,900
On April 12, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 12, King Bridge Investments Limited sold $310,000 common shares worth HK$1,520,900 at an average price of HK$4.9062 per share on April 12. After the sale, King Bridge Investments Limited's latest shareholding was 106 million shares, and the good position ratio dropped from 6.01% to 5.99%. Photo Source: Stock Exchange Shareholding Disclosure
Nuocheng Jianhua (9969.HK): Many products whose performance is in line with expectations will soon be submitted for NDA
Introduction to this report: Obutinib's revenue in 2023 was 671 million yuan (+18.5%). Clinical progress for hematomas, immunization, and solid tumors is progressing smoothly. Various drugs are expected to be submitted to the NDA in 2024. We are optimistic about the company's future development and maintenance
Looking for new pharmaceutical productivity: Looking at the high-quality development of local innovative pharmaceutical companies from Nuochengjianhua (9969.HK/688428.SH)
“New quality productivity” is becoming one of the most popular terms recently. In March 2024, the report on the work of the Chinese government identified “developing new quality productivity” as the top priority at present. Among them, innovative drugs are clearly mentioned for the first time in the “Actively Cultivating Emerging Industries and Future Industries” section, stating that it is necessary to “accelerate the development of the cutting-edge and emerging innovative drug industry, actively build a new growth engine for biomantry manufacturing, open up a new life science circuit, and create a number of pioneering zones for future industries” to add another spring breeze to the innovative drug circuit. Well, in an age where the innovative drug industry is receiving so much attention from top-level design, it
Read Nuochengjianhua's 2023 performance report in one picture
On March 28, Nuochengjianhua announced its 2023 performance report. The following will take you to read Nuochengjianhua's 2023 performance report with a picture.
Press Release: InnoCare Releases 2023 Results and Business Highlights
InnoCare Releases 2023 Results and Business Highlights BEIJING--(BUSINESS WIRE)--March 28, 2024-- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer a
No Data